Distasio Nicholas, Dierick France, Ebrahimian Talin, Tabrizian Maryam, Lehoux Stephanie
Department of Biomedical Engineering, McGill University 3773 University, Montreal, QC H3A 2B6, Canada.
Lady Davis Institute, Department of Medicine, McGill University, 3755 Chemin de la Côte-Sainte-Catherine, Montreal, QC H3T 1E2, Canada.
Acta Biomater. 2022 Apr 15;143:356-371. doi: 10.1016/j.actbio.2022.02.043. Epub 2022 Mar 5.
Atherosclerosis progression is a result of chronic and non-resolving inflammation, effective treatments for which still remain to be developed. We designed and developed branched poly(ß-amino ester) nanoparticles (NPs) containing plasmid DNA encoding IL-10, a potent anti-inflammatory cytokine to atherosclerosis. The NPs (NP-VHPK) are functionalized with a targeting peptide (VHPK) specific for VCAM-1, which is overexpressed by endothelial cells at sites of atherosclerotic plaque. The anionic coating affords NP-VHPK with significantly lower toxicity than uncoated NPs in both endothelial cells and red blood cells (RBCs). Following injection of NP-VHPK in ApoE mice, Cy5-labelled IL-10 significantly accumulates in both whole aortas and aortic sinus sections containing plaque compared to injection with a non-targeted control. Furthermore, IL-10 gene delivery results in an attenuation of inflammation locally at the plaque site. NP-VHPK may thus have the potential to reduce the inflammatory component of atherosclerosis in a safe and effective manner. STATEMENT OF SIGNIFICANCE: Atherosclerosis is a chronic inflammatory disease that results in the formation of lipid-laden plaques within vascular walls. Although treatments using drugs and antibodies are now beginning to address the inflammation in atherosclerosis, neither is sufficient for long-term therapy. In this paper, we introduce a strategy to deliver genes encoding the anti-inflammatory protein interleukin-10 (IL-10) in vivo. We showed that Branched Poly(ß-aminoester) carrying the IL-10 gene are able to localize specifically at the plaque via surface-functionalized targeting moieties against inflamed VCAM-1 and/or ICAM-1 and to facilitate gene transcription by ECs to increase the local concentration of the IL-10 within the plaque. To date, there is no report involving non-viral nanotechnology to provide gene-based therapies for atherosclerosis.
动脉粥样硬化进展是慢性且无法消退的炎症的结果,针对这一炎症的有效治疗方法仍有待开发。我们设计并开发了包含编码白细胞介素-10(IL-10)的质粒DNA的支化聚(β-氨基酯)纳米颗粒(NPs),IL-10是一种对动脉粥样硬化具有强大抗炎作用的细胞因子。这些纳米颗粒(NP-VHPK)用对血管细胞黏附分子-1(VCAM-1)具有特异性的靶向肽(VHPK)进行功能化修饰,VCAM-1在动脉粥样硬化斑块部位的内皮细胞中过度表达。与未包被的纳米颗粒相比,阴离子涂层使NP-VHPK在内皮细胞和红细胞(RBCs)中的毒性显著降低。在载脂蛋白E小鼠中注射NP-VHPK后,与注射非靶向对照相比,Cy5标记的IL-10在整个主动脉和含有斑块的主动脉窦切片中均显著蓄积。此外,IL-10基因递送导致斑块部位局部炎症减轻。因此,NP-VHPK可能有潜力以安全有效的方式降低动脉粥样硬化的炎症成分。重要性声明:动脉粥样硬化是一种慢性炎症性疾病,会导致血管壁内形成富含脂质的斑块。尽管目前使用药物和抗体的治疗方法已开始针对动脉粥样硬化中的炎症,但两者都不足以进行长期治疗。在本文中,我们介绍了一种在体内递送编码抗炎蛋白白细胞介素-10(IL-10)的基因的策略。我们表明,携带IL-10基因的支化聚(β-氨基酯)能够通过针对炎症性VCAM-1和/或ICAM-1的表面功能化靶向部分特异性地定位于斑块,并促进内皮细胞进行基因转录,以增加斑块内IL-10的局部浓度。迄今为止,尚无关于使用非病毒纳米技术为动脉粥样硬化提供基于基因的治疗方法的报道。